OPPM
SRPT icon

Opus Point Partners Management’s Sarepta Therapeutics SRPT Stock Holding History

Opus Point Partners Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,353
Closed -$813K – 63
2019
Q2 		$813K Buy
5,353
+2,101
+65% +$255K 1.2% 19
2019
Q1 		$388K Buy
+3,252
New +$418K 0.53% 48

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Opus Point Partners Management's SRPT Position: Q3 2019 in Review

Opus Point Partners Management sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 5,353 shares — an estimated $813K sold.

Opus Point Partners Management first reported a position in SRPT in Q1 2019 and held it in 2 quarters. The position peaked at $813K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Opus Point Partners Management reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 5,353 Sarepta Therapeutics shares in Q3 2019, an estimated $813K.
  • Opus Point Partners Management first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 2 quarters.
  • Opus Point Partners Management's Sarepta Therapeutics position peaked at $813K in Q2 2019.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.